{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:00:55Z","timestamp":1791979255139,"version":"4.4.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Meningiomas are the most common primary brain tumor in adults. Traditionally they have been understudied compared to other central nervous system (CNS) tumors. However over the last decade, there has been renewed interest in uncovering the molecular topography of these tumors, with landmark studies identifying key driver alterations contributing to meningioma development and progression. Recent work from several independent research groups have integrated different genomic and epigenomic platforms to develop a molecular-based classification scheme for meningiomas that could supersede histopathological grading in terms of diagnostic accuracy, biological relevance, and outcome prediction, keeping pace with contemporary grading schemes for other CNS tumors including gliomas and medulloblastomas.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Here we summarize the studies that have uncovered key alterations in meningiomas which builds towards the discovery of consensus molecular groups in meningiomas by integrating these findings. These groups supersede WHO grade and other clinical factors in being able to accurately predict tumor biology and clinical outcomes following surgery.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Despite differences in the nomenclature of recently uncovered molecular groups across different studies, the biological similarities between these groups enables us to likely reconciliate these groups into four consensus molecular groups: two benign groups largely dichotomized by <jats:italic>NF2<\/jats:italic>-status, and two clinically aggressive groups defined by their hypermetabolic transcriptome, and by their preponderance of proliferative, cell-cycling pathways respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Future work, including by our group and others are underway to validate these molecular groups and harmonize the nomenclature for routine clinical use.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11060-023-04253-2","type":"journal-article","created":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T11:02:44Z","timestamp":1677322964000},"page":"405-414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The multiomic landscape of meningiomas: a review and update"],"prefix":"10.1007","volume":"161","author":[{"given":"Justin Z.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad","family":"Nassiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander P.","family":"Landry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Aldape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gelareh","family":"Zadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,25]]},"reference":[{"issue":"12 Suppl 2","key":"4253_CR1","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","volume":"23","author":"QT Ostrom","year":"2021","unstructured":"Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2021) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014\u20132018. Neuro Oncol 23(12 Suppl 2):iii1\u2013iii105","journal-title":"Neuro Oncol"},{"issue":"11","key":"4253_CR2","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","volume":"23","author":"R Goldbrunner","year":"2021","unstructured":"Goldbrunner R, Stavrinou P, Jenkinson MD et al (2021) EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol 23(11):1821\u20131834","journal-title":"Neuro Oncol"},{"issue":"2","key":"4253_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11060-021-03874-9","volume":"156","author":"SM Robert","year":"2022","unstructured":"Robert SM, Vetsa S, Nadar A et al (2022) The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications. J Neuro Oncol 156(2):205\u2013214","journal-title":"J Neuro Oncol"},{"issue":"4","key":"4253_CR4","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/0092-8674(93)90501-G","volume":"75","author":"JA Trofatter","year":"1993","unstructured":"Trofatter JA, MacCollin MM, Rutter JL et al (1993) A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 75(4):826","journal-title":"Cell"},{"issue":"6429","key":"4253_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/363515a0","volume":"363","author":"GA Rouleau","year":"1993","unstructured":"Rouleau GA, Merel P, Lutchman M et al (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363(6429):515\u2013521","journal-title":"Nature"},{"issue":"4","key":"4253_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.cell.2010.01.029","volume":"140","author":"W Li","year":"2010","unstructured":"Li W, You L, Cooper J et al (2010) Merlin\/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 140(4):477\u2013490","journal-title":"Cell"},{"key":"4253_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020690","author":"S Bachir","year":"2021","unstructured":"Bachir S, Shah S, Shapiro S et al (2021) Neurofibromatosis Type 2 (NF2) and the implications for vestibular schwannoma and meningioma pathogenesis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22020690","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4253_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ng0294-180","volume":"6","author":"MH Ruttledge","year":"1994","unstructured":"Ruttledge MH, Sarrazin J, Rangaratnam S et al (1994) Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 6(2):180\u2013184","journal-title":"Nat Genet"},{"issue":"1","key":"4253_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/humu.20393","volume":"28","author":"I Ahronowitz","year":"2007","unstructured":"Ahronowitz I, Xin W, Kiely R, Sims K, MacCollin M, Nunes FP (2007) Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings. Hum Mutat 28(1):1\u201312","journal-title":"Hum Mutat"},{"issue":"3","key":"4253_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/ng.2526","volume":"45","author":"PK Brastianos","year":"2013","unstructured":"Brastianos PK, Horowitz PM, Santagata S et al (2013) Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45(3):285\u2013289","journal-title":"Nat Genet"},{"issue":"6123","key":"4253_CR11","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1126\/science.1233009","volume":"339","author":"VE Clark","year":"2013","unstructured":"Clark VE, Erson-Omay EZ, Serin A et al (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339(6123):1077\u20131080","journal-title":"Science"},{"issue":"2","key":"4253_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/ncb1086","volume":"6","author":"T Bouwmeester","year":"2004","unstructured":"Bouwmeester T, Bauch A, Ruffner H et al (2004) A physical and functional map of the human TNF-alpha\/NF-kappa B signal transduction pathway. Nat Cell Biol 6(2):97\u2013105","journal-title":"Nat Cell Biol"},{"issue":"5","key":"4253_CR13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Tanabe K, Ohnuki M et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861\u2013872","journal-title":"Cell"},{"issue":"10","key":"4253_CR14","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41556-019-0390-6","volume":"21","author":"DC Di Giammartino","year":"2019","unstructured":"Di Giammartino DC, Kloetgen A, Polyzos A et al (2019) KLF4 is involved in the organization and regulation of pluripotency-associated three-dimensional enhancer networks. Nat Cell Biol 21(10):1179\u20131190","journal-title":"Nat Cell Biol"},{"issue":"7152","key":"4253_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nature05933","volume":"448","author":"JD Carpten","year":"2007","unstructured":"Carpten JD, Faber AL, Horn C et al (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448(7152):439\u2013444","journal-title":"Nature"},{"issue":"6662","key":"4253_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/34201","volume":"391","author":"J Xie","year":"1998","unstructured":"Xie J, Murone M, Luoh SM et al (1998) Activating smoothened mutations in sporadic basal-cell carcinoma. Nature 391(6662):90\u201392","journal-title":"Nature"},{"issue":"10","key":"4253_CR17","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/ng.3651","volume":"48","author":"VE Clark","year":"2016","unstructured":"Clark VE, Harmanc\u0131 AS, Bai H et al (2016) Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet 48(10):1253\u20131259","journal-title":"Nat Genet"},{"issue":"1","key":"4253_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10048-009-0204-2","volume":"11","author":"C Bacci","year":"2010","unstructured":"Bacci C, Sestini R, Provenzano A et al (2010) Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation. Neurogenetics 11(1):73\u201380","journal-title":"Neurogenetics"},{"issue":"2","key":"4253_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1136\/jmg.2010.082420","volume":"48","author":"I Christiaans","year":"2011","unstructured":"Christiaans I, Kenter S, Brink H et al (2011) Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas. J Med Genet 48(2):93\u201397","journal-title":"J Med Genet"},{"issue":"8","key":"4253_CR20","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/jmg.2009.075721","volume":"47","author":"KD Hadfield","year":"2010","unstructured":"Hadfield KD, Smith MJ, Trump D, Newman WG, Evans D (2010) SMARCB1 mutations are not a common cause of multiple meningiomas. J Med Genet 47(8):567\u2013568","journal-title":"J Med Genet"},{"issue":"4","key":"4253_CR21","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1086\/513207","volume":"80","author":"TJ Hulsebos","year":"2007","unstructured":"Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P (2007) Germline mutation of INI1\/SMARCB1 in familial schwannomatosis. Am J Hum Genet 80(4):805\u2013810","journal-title":"Am J Hum Genet"},{"issue":"6122","key":"4253_CR22","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1126\/science.1229259","volume":"339","author":"FW Huang","year":"2013","unstructured":"Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339(6122):957\u2013959","journal-title":"Science"},{"issue":"5","key":"4253_CR23","doi-asserted-by":"publisher","first-page":"djv377","DOI":"10.1093\/jnci\/djv377","volume":"108","author":"F Sahm","year":"2016","unstructured":"Sahm F, Schrimpf D, Olar A et al (2016) TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst 108(5):djv377","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"4253_CR24","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231\u20131251","journal-title":"Neuro Oncol"},{"issue":"12","key":"4253_CR25","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/neuonc\/noy104","volume":"20","author":"S Spiegl-Kreinecker","year":"2018","unstructured":"Spiegl-Kreinecker S, L\u00f6tsch D, Neumayer K et al (2018) TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma. Neuro Oncol 20(12):1584\u20131593","journal-title":"Neuro Oncol"},{"issue":"3","key":"4253_CR26","first-page":"296","volume":"16","author":"LT Evans","year":"2015","unstructured":"Evans LT, Van Hoff J, Hickey WF et al (2015) SMARCE1 mutations in pediatric clear cell meningioma: case report. J Neurosurg 16(3):296\u2013300","journal-title":"J Neurosurg"},{"issue":"2","key":"4253_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10048-015-0472-y","volume":"17","author":"E Gerkes","year":"2016","unstructured":"Gerkes E, Fock J, den Dunnen W et al (2016) A heritable form of SMARCE1-related meningiomas with important implications for follow-up and family screening. Neurogenetics 17(2):83\u201389","journal-title":"Neurogenetics"},{"issue":"4","key":"4253_CR28","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bpa.12524","volume":"28","author":"A Tauziede-Espariat","year":"2018","unstructured":"Tauziede-Espariat A, Parfait B, Besnard A et al (2018) Loss of SMARCE1 expression is a specific diagnostic marker of clear cell meningioma: a comprehensive immunophenotypical and molecular analysis. Brain Pathol 28(4):466\u2013474","journal-title":"Brain Pathol"},{"issue":"6","key":"4253_CR29","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41588-022-01077-0","volume":"54","author":"R St. Pierre","year":"2022","unstructured":"St. Pierre R, Collings CK, Sam\u00e9 Guerra DD et al (2022) SMARCE1 deficiency generates a targetable mSWI\/SNF dependency in clear cell meningioma. Nat Genet 54(6):861\u2013873","journal-title":"Nat Genet"},{"issue":"3","key":"4253_CR30","doi-asserted-by":"publisher","first-page":"270","DOI":"10.21037\/tlcr.2017.05.03","volume":"6","author":"M Cheung","year":"2017","unstructured":"Cheung M, Testa JR (2017) BAP1, a tumor suppressor gene driving malignant mesothelioma. Transl Lung Cancer Res 6(3):270","journal-title":"Transl Lung Cancer Res"},{"key":"4253_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2021-207952","author":"AP Landry","year":"2021","unstructured":"Landry AP, Wang JZ, Nassiri F, Patil V, Gao A, Zadeh G (2021) BAP1-deficient meningioma presenting with trabecular architecture and cytokeratin expression: a report of two cases and review of the literature. J Clin Pathol. https:\/\/doi.org\/10.1136\/jclinpath-2021-207952","journal-title":"J Clin Pathol"},{"issue":"11","key":"4253_CR32","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/neuonc\/nox094","volume":"19","author":"GM Shankar","year":"2017","unstructured":"Shankar GM, Santagata S (2017) BAP1 mutations in high-grade meningioma: implications for patient care. Neuro Oncol 19(11):1447\u20131456","journal-title":"Neuro Oncol"},{"issue":"3","key":"4253_CR33","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/ijc.2910560310","volume":"56","author":"A Lindblom","year":"1994","unstructured":"Lindblom A, Ruttledge M, Collins VP, Nordenskj\u00f6ld M, Dumanski JP (1994) Chromosomal deletions in anaplastic meningiomas suggest multiple regions outside chromosome 22 as important in tumor progression. Int J Cancer 56(3):354\u2013357","journal-title":"Int J Cancer"},{"issue":"15","key":"4253_CR34","first-page":"3226","volume":"58","author":"EP Sulman","year":"1998","unstructured":"Sulman EP, Dumanski JP, White PS et al (1998) Identification of a consistent region of allelic loss on 1p32 in meningiomas: correlation with increased morbidity. Cancer Res 58(15):3226\u20133230","journal-title":"Cancer Res"},{"issue":"7","key":"4253_CR35","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1158\/0008-5472.CAN-04-3651","volume":"65","author":"PG Buckley","year":"2005","unstructured":"Buckley PG, Jarbo C, Menzel U et al (2005) Comprehensive DNA copy number profiling of meningioma using a chromosome 1 tiling path microarray identifies novel candidate tumor suppressor loci. Cancer Res 65(7):2653\u20132661","journal-title":"Cancer Res"},{"issue":"1","key":"4253_CR36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S0165-4608(99)00249-6","volume":"120","author":"MJ Bello","year":"2000","unstructured":"Bello MJ, de Campos JM, Vaquero J, Kusak ME, Sarasa JL, Rey JA (2000) High-resolution analysis of chromosome arm 1p alterations in meningioma. Cancer Genet Cytogenet 120(1):30\u201336","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"4253_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41525-016-0002-3","volume":"2","author":"WL Bi","year":"2017","unstructured":"Bi WL, Greenwald NF, Abedalthagafi M et al (2017) Genomic landscape of high-grade meningiomas. NPJ Genom Med 2(1):1\u201314","journal-title":"NPJ Genom Med"},{"issue":"4","key":"4253_CR38","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1750-3639.2009.00356.x","volume":"20","author":"Y Lee","year":"2010","unstructured":"Lee Y, Liu J, Patel S et al (2010) Genomic landscape of meningiomas. Brain Pathol 20(4):751\u2013762","journal-title":"Brain Pathol"},{"issue":"3","key":"4253_CR39","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3171\/2015.6.JNS15591","volume":"125","author":"WL Bi","year":"2016","unstructured":"Bi WL, Abedalthagafi M, Horowitz P et al (2016) Genomic landscape of intracranial meningiomas. J Neurosurg 125(3):525\u2013535","journal-title":"J Neurosurg"},{"key":"4253_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab213","author":"J Driver","year":"2021","unstructured":"Driver J, Hoffman SE, Tavakol S et al (2021) A molecularly integrated grade for meningioma. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noab213","journal-title":"Neuro Oncol"},{"issue":"2","key":"4253_CR41","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0002-9440(10)61737-3","volume":"159","author":"J Bostr\u00f6m","year":"2001","unstructured":"Bostr\u00f6m J, Meyer-Puttlitz B, Wolter M et al (2001) Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol 159(2):661\u2013669","journal-title":"Am J Pathol"},{"key":"4253_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ebiom.2016.04.017","volume":"8","author":"R Zhao","year":"2016","unstructured":"Zhao R, Choi BY, Lee MH, Bode AM, Dong Z (2016) Implications of genetic and epigenetic alterations of CDKN2A (p16(INK4a)) in cancer. EBioMedicine 8:30\u201339","journal-title":"EBioMedicine"},{"issue":"3","key":"4253_CR43","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00401-020-02188-w","volume":"140","author":"P Sievers","year":"2020","unstructured":"Sievers P, Hielscher T, Schrimpf D et al (2020) CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol 140(3):409\u2013413","journal-title":"Acta Neuropathol"},{"issue":"3","key":"4253_CR44","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00401-017-1678-x","volume":"133","author":"A Olar","year":"2017","unstructured":"Olar A, Wani KM, Wilson CD et al (2017) Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. Acta Neuropathol 133(3):431\u2013444","journal-title":"Acta Neuropathol"},{"issue":"5","key":"4253_CR45","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","volume":"18","author":"F Sahm","year":"2017","unstructured":"Sahm F, Schrimpf D, Stichel D et al (2017) DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 18(5):682\u2013694","journal-title":"Lancet Oncol"},{"issue":"7","key":"4253_CR46","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/neuonc\/noz061","volume":"21","author":"F Nassiri","year":"2019","unstructured":"Nassiri F, Mamatjan Y, Suppiah S et al (2019) DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro Oncol 21(7):901\u2013910","journal-title":"Neuro Oncol"},{"issue":"7663","key":"4253_CR47","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nature22973","volume":"547","author":"PA Northcott","year":"2017","unstructured":"Northcott PA, Buchhalter I, Morrissy AS et al (2017) The whole-genome landscape of medulloblastoma subtypes. Nature 547(7663):311\u2013317","journal-title":"Nature"},{"issue":"26","key":"4253_CR48","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","volume":"372","author":"DJ Brat","year":"2015","unstructured":"Brat DJ, Verhaak RG, Aldape KD et al (2015) Comprehensive, Integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372(26):2481\u20132498","journal-title":"N Engl J Med"},{"issue":"26","key":"4253_CR49","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","volume":"372","author":"JE Eckel-Passow","year":"2015","unstructured":"Eckel-Passow JE, Lachance DH, Molinaro AM et al (2015) Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372(26):2499\u20132508","journal-title":"N Engl J Med"},{"issue":"7874","key":"4253_CR50","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","volume":"597","author":"F Nassiri","year":"2021","unstructured":"Nassiri F, Liu J, Patil V et al (2021) A clinically applicable integrative molecular classification of meningiomas. Nature 597(7874):119\u2013125","journal-title":"Nature"},{"issue":"5","key":"4253_CR51","doi-asserted-by":"publisher","first-page":"eabm6247","DOI":"10.1126\/sciadv.abm6247","volume":"8","author":"JCt Bayley","year":"2022","unstructured":"Bayley JCt, Hadley CC, Harmanci AO, Harmanci AS, Klisch TJ, Patel AJ (2022) Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies. Sci Adv 8(5):eabm6247","journal-title":"Sci Adv"},{"issue":"5","key":"4253_CR52","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","volume":"54","author":"A Choudhury","year":"2022","unstructured":"Choudhury A, Magill ST, Eaton CD et al (2022) Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat Genet 54(5):649\u2013659","journal-title":"Nat Genet"},{"key":"4253_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac224","author":"A Choudhury","year":"2022","unstructured":"Choudhury A, Chen WC, Lucas CG et al (2022) Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noac224","journal-title":"Neuro Oncol"},{"issue":"1","key":"4253_CR54","first-page":"vdab085","volume":"3","author":"C Horbinski","year":"2021","unstructured":"Horbinski C, Xi G, Wang Y et al (2021) The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma. Neurooncol Adv. 3(1):vdab085","journal-title":"Neurooncol Adv."},{"issue":"3","key":"4253_CR55","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.ijrobp.2011.08.010","volume":"83","author":"S Adeberg","year":"2012","unstructured":"Adeberg S, Hartmann C, Welzel T et al (2012) Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas\u2014Clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. Int J Rad Oncol Biol Phys 83(3):859\u2013864","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"11","key":"4253_CR56","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/neuonc\/nou098","volume":"16","author":"AA Aizer","year":"2014","unstructured":"Aizer AA, Arvold ND, Catalano P et al (2014) Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro Oncol 16(11):1547\u20131553","journal-title":"Neuro Oncol"},{"issue":"15","key":"4253_CR57","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1200\/JCO.2001.19.15.3547","volume":"19","author":"J Debus","year":"2001","unstructured":"Debus J, Wuendrich M, Pirzkall A et al (2001) High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: long-term results. J Clin Oncol 19(15):3547\u20133553","journal-title":"J Clin Oncol"},{"issue":"4","key":"4253_CR58","first-page":"e567","volume":"8","author":"M Amsbaugh","year":"2016","unstructured":"Amsbaugh M, Ugiliweneza B, Burton E, Skirboll S, Woo S, Boakye M (2016) Patterns of care and outcomes of adjuvant radiotherapy for meningiomas: a surveillance, epidemiology, and end results and medicare linked analysis. Cureus 8(4):e567","journal-title":"Cureus"},{"issue":"2","key":"4253_CR59","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3171\/2016.11.JNS161402","volume":"128","author":"O Cohen-Inbar","year":"2018","unstructured":"Cohen-Inbar O, Tata A, Moosa S, Lee CC, Sheehan JP (2018) Stereotactic radiosurgery in the treatment of parasellar meningiomas: long-term volumetric evaluation. J Neurosurg 128(2):362\u2013372","journal-title":"J Neurosurg"},{"issue":"1","key":"4253_CR60","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/1971400917744885","volume":"31","author":"R Di Franco","year":"2018","unstructured":"Di Franco R, Borzillo V, Ravo V et al (2018) Radiosurgery and stereotactic radiotherapy with cyberknife system for meningioma treatment. Neuroradiol J 31(1):18\u201326","journal-title":"Neuroradiol J"},{"issue":"5","key":"4253_CR61","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.ijrobp.2004.05.073","volume":"60","author":"SJ DiBiase","year":"2004","unstructured":"DiBiase SJ, Kwok Y, Yovino S et al (2004) Factors predicting local tumor control after gamma knife stereotactic radiosurgery for benign intracranial meningiomas. Int J Radiat Oncol Biol Phys 60(5):1515\u20131519","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04253-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-023-04253-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04253-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T10:11:11Z","timestamp":1678097471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-023-04253-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["4253"],"URL":"https:\/\/doi.org\/10.1007\/s11060-023-04253-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"19 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}